Longevity & AgingDapansutrile, an oral NLRP3 inhibitor, shows broad anti-inflammatory promise from gout to aging
Dapansutrile (OLT1177) is an oral, selective NLRP3 inflammasome inhibitor. It binds the NLRP3 NACHT domain, blocks inflammasome assembly and caspase-1 activation, and reduces IL-1β and IL-18 release. This narrative review gathers preclinical and early clinical evidence across gout, periodontitis, Alzheimer's and Parkinson's models, heart failure, inflammaging, and cancer immunotherapy. In a phase 2a gout study, pain fell 82-89% by day 7 and IL-6 dropped. In mice, it reversed Alzheimer's-like cognitive deficits and cut infarct size by 71%. It also extended survival in progeria mice when combined with lonafarnib. Safety looks favorable, with no hepatotoxicity reported, unlike MCC950. Most evidence is animal data or small trials, so human efficacy remains unproven.
